European Journal of Clinical Pharmacology

, Volume 63, Issue 11, pp 1011–1017 | Cite as

Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study

  • Réginald HulhovenEmail author
  • Dominique Rosillon
  • Michel Letiexhe
  • Marie-Anne Meeus
  • Agnès Daoust
  • Armel Stockis



To conduct a thorough QT study of levocetirizine, a non-sedating antihistamine, in accordance with International Conference on Harmonisation (ICH) E14 guidance.


The study was designed as a single-dose, placebo and positive-controlled, four-way crossover, randomised trial in which 52 healthy male and female subjects participated. Levocetirizine (5 and 30 mg) and placebo were administered double-blind, and the positive control, moxifloxacin (400 mg), was open-label. Electrocardiograms (ECGs) were obtained by continuous Holter monitoring at various time points (three per time point) during a 24-h period at baseline and after each treatment. The ECGs were read centrally in a blinded manner. QT intervals were corrected for heart rate using a gender- and study-specific correction (QTcSS) and Fridericia’s correction (QTcF). The largest QTc time-matched and baseline-subtracted difference between each active drug and the placebo (largest ΔΔQTcSS) was derived from a mixed-effect analysis of variance.


The one-sided 95% upper limits of the largest ΔΔQTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively. Similar results were obtained for the ΔΔQTcF data. Statistically, moxifloxacin significantly lengthened the QTcSS, with a one-sided 95% lower limit of the largest ΔΔQTcSS of 10.5 ms and a mean estimate of 13.4 ms. There was no relationship between the measured ΔQTcSS and the plasma concentration of levocetirizine, whereas a statistically significant linear relationship was observed with the plasma concentration of moxifloxacin [slope estimate 0.004 ms/(ng/mL); 95% confidence interval: 0.003–0.005].


Overall, the results of this thorough QT study indicate that the methodology of the trial was valid and sensitive enough to demonstrate the absence of effect of levocetirizine at both therapeutic (5 mg) and supra-therapeutic (30 mg) doses on cardiac repolarisation.


ICH E14 guideline Levocetirizine QT/QTc interval Thorough QT study 



We are grateful to Shikiko Watanabe, Javier Sawchik and Mona Mihaela Troenaru for their aid in reviewing and analysing the results of this study, and to Dr Joel Morganroth for expert advice. We declare that the study reported herein complied with the current laws of the country in which it was performed.


  1. 1.
    Devalia JL, De Vos C, Hanotte F, Baltes E (2001) A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 56:50–57PubMedCrossRefGoogle Scholar
  2. 2.
    Wang DY, Hanotte F, De Vos C, Clement P (2001) Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy 56:339–343PubMedCrossRefGoogle Scholar
  3. 3.
    Baltes E, Coupez R, Giezek H, Voss G, Meyerhoff C, et al (2001) Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 15:269–277PubMedCrossRefGoogle Scholar
  4. 4.
    Strolin-Benedetti M, Plisnier M, Kaise J, Maier L, Baltes E, et al (2001) Absorption, distribution, metabolism and excretion of [14C] levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol 57:571–582CrossRefGoogle Scholar
  5. 5.
    Paakkari I (2002) Cardiotoxicity of new antihistamines and cisapride (review article). Toxicol Lett 127:279–284PubMedCrossRefGoogle Scholar
  6. 6.
    ICH Guidance (2005) Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. E14, Step 4, ICH Steering CommitteeGoogle Scholar
  7. 7.
    Morganroth J (2001) Focus on issues in measuring and interpreting changes in the QTc interval duration. Eur Heart J [Suppl 3]:K105–K111Google Scholar
  8. 8.
    Morganroth J (2004) A definitive or thorough Phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol 37:25–29PubMedCrossRefGoogle Scholar
  9. 9.
    Darpo B, Nebout T, Sager PT (2006) Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs. In: Int 9th Conf Harmonization Tech Requirements Registration Pharmaceuticals Human Use E14 Guideline. J Clin Pharmacol 46:498–507Google Scholar
  10. 10.
    Grisanti S, Morganroth J, Shah RR (2005) A practical approach to cardiac safety: Implementing ICH E14 to define cardiac safety in new drug development. Appl Clin Trials Suppl October 2005, pp 10–16Google Scholar
  11. 11.
    Patterson SD (on behalf of Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team) (2005) Investigating drug-induced QT and QTc prolongation in the clinic: A review of statistical design and analysis considerations. Drug Inf J 39:243–266Google Scholar
  12. 12.
    Shah RR (2005) Drugs, QTc interval prolongation and final ICH E14 guideline: An important milestone with challenges ahead. Drug Safety 28:1009–1028PubMedCrossRefGoogle Scholar
  13. 13.
    Sale ME, Barbey JT, Woosley RL, Edwards D, Yeh J, et al (1994) The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 56:295–301PubMedGoogle Scholar
  14. 14.
    Hussein Z, Pitsiu M, Aarons L et al (2005) Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study. Br J Clin Pharmacol 59:28–37PubMedCrossRefGoogle Scholar
  15. 15.
    Williams GC, Dunnington KM, Hu MY, Zimmerman TR Jr, Wang Z, Hafner KB, et al (2006) The impact of posture on cardiac repolarization: more than heart rate? J Cardiovasc Electrophysiol 17:352–358PubMedCrossRefGoogle Scholar
  16. 16.
    Stass H, Dalhoff A, Kubitza D, Schuhly U (1998) Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents and Chemother 42:2060–2065PubMedGoogle Scholar
  17. 17.
    Stass H, Kubitza D, Schuhly U (2001) Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 40[Suppl1]:1–9PubMedCrossRefGoogle Scholar
  18. 18.
    Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, et al (1999) Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 43:2793–2797PubMedGoogle Scholar
  19. 19.
    Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantelina LR (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788–2790PubMedCrossRefGoogle Scholar
  20. 20.
    Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantelina LR (1993) Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 269:1513–1518PubMedCrossRefGoogle Scholar
  21. 21.
    DuBuske LM (1999) Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 21:281–295CrossRefGoogle Scholar
  22. 22.
    Morganroth J (2007) Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 81:108–113PubMedCrossRefGoogle Scholar
  23. 23.
    Sun H (2007) Pharmacometric methods for assessing drug-induced QT and QTc prolongations for non-antiarrhythmic drugs. In: Ette EI, Williams PJ (eds) Pharmacometrics: the science of quantitative pharmacology. John Wileys & Sons, New York, pp 977–992Google Scholar
  24. 24.
    Skerjanec A, Affrime MB, Milosavljev S, et al (2005) Darifenacin, an M3 selective receptor antagonist (M3 SAR), does not prolong QT/QTc. Clin Pharmacol Ther 79:P10CrossRefGoogle Scholar
  25. 25.
    Harris SC, Hoelscher D, Krisensen A, O’Keefe SA, et al (2005) Effect of buprenorphine transdermal system 10 mg and 2 × 20 mg on QT intervals in healthy subjects. Clin Pharmacol Ther 79:P35Google Scholar
  26. 26.
    Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R (2003) Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 73:292–303PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Réginald Hulhoven
    • 1
    Email author
  • Dominique Rosillon
    • 1
  • Michel Letiexhe
    • 2
  • Marie-Anne Meeus
    • 1
  • Agnès Daoust
    • 1
  • Armel Stockis
    • 1
  1. 1.Clinical PharmacologyUCB Pharma SABraine-l’AlleudBelgium
  2. 2.Clinical PharmacologyUniversity Hospital CentreLiègeBelgium

Personalised recommendations